» Articles » PMID: 36852004

The Impact of Corticosteroids on the Outcome of Fungal Disease: a Systematic Review and Meta-analysis

Overview
Date 2023 Feb 28
PMID 36852004
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: Corticosteroids have a complex relationship with fungal disease - risk for many, benefit for others. This systematic review aims to address the effect of corticosteroids on mortality and visual outcome in different fungal diseases.

Recent Findings: Corticosteroids are a risk factor of aspergillosis for patients who have COVID-19, and they also led to a worse outcome. Similarity, corticosteroids are a risk factor for candidemia and mucormycosis. Some researchers reported that using topical corticosteroid in keratitis was associated with worse visual outcome if fungal keratitis. Some studies showed that corticosteroids are linked to a negative outcome for non-HIV patients with pneumonia (PCP), in contrast to those with HIV and PCP.

Summary: In 59 references, we found that corticosteroid therapy showed a worse clinical outcome in invasive aspergillosis (IA) (HR: 2.50, 95%CI: 1.89-3.31,  < 0.001) and chronic pulmonary aspergillosis (CPA) (HR: 2.74, 95%CI: 1.48-5.06,  = 0.001), PCP without HIV infection (OR: 1.29, 95%CI: 1.09-1.53,  = 0.003), invasive candidiasis and candidaemia (OR: 2.13, 95%CI: 1.85-2.46,  < 0.001), mucormycosis (OR: 4.19, 95%CI: 1.74-10.05,  = 0.001) and early in the course of fungal keratitis (OR: 2.99, 95%CI: 1.14-7.84,  = 0.026). There was equivocal outcome in cryptococcal meningoencephalitis in AIDS and primary coccidioidomycosis, while corticosteroid therapy showed a better outcome in PCP in HIV-infected patients (RR: 0.62, 95%CI: 0.46-0.83, =0.001) and fungal keratitis patients after keratoplasty surgery (OR: 0.01, 95%CI: 0.00-0.41,  = 0.041) and probably in cryptococcal meningoencephalitis in non-immunocompromised patients. A sub-analysis in invasive aspergillosis and CPA showed that use of more than 2 mg/kg/day of prednisolone equivalents per day is a significant factor in increasing mortality (HR: 2.94, 95%CI: 2.13-4.05,  < 0.001). Corticosteroid therapy during invasive fungal disease was usually associated with a slightly or greatly increased mortality or worse visual outcome (in fungal keratitis), with two disease exceptions. Avoiding the addition of corticosteroids, or minimising dose and duration in those who require them, is likely to improve the outcome of most life- and vision-threatening fungal diseases. This review provides a cornerstone for further research in exploring the accuracy of suitable dose and duration of corticosteroids treatment in fungal diseases.

Supplementary Information: The online version contains supplementary material available at 10.1007/s12281-023-00456-2.

Citing Articles

Favourable outcome of prosthetic valve endocarditis in a patient with an Ebstein anomaly.

Lee-Jones S, van der Westhuizen S, Taljaard J, Govender N, Razack R S Afr J Infect Dis. 2025; 40(1):699.

PMID: 40060086 PMC: 11886575. DOI: 10.4102/sajid.v40i1.699.


Fungal-Induced Hemophagocytic Lymphohistiocytosis: A Literature Review in Non-HIV Populations.

Chiu C, Hicklen R, Kontoyiannis D J Fungi (Basel). 2025; 11(2).

PMID: 39997452 PMC: 11856227. DOI: 10.3390/jof11020158.


Unveiling ferroptosis genes and inhibitors in diabetic retinopathy through single-cell analysis and docking simulations.

Khan M, Ganguly A, Barman S, Das C, Ganesan S Biochem Biophys Rep. 2025; 41:101932.

PMID: 39968183 PMC: 11833632. DOI: 10.1016/j.bbrep.2025.101932.


Current Analytical Methods and Challenges for the Clinical Diagnosis of Invasive Pulmonary Aspergillosis Infection.

Schwarz M, Moskaluk A, Daniels J, VandeWoude S, Reynolds M J Fungi (Basel). 2024; 10(12).

PMID: 39728325 PMC: 11676737. DOI: 10.3390/jof10120829.


Candidemia chronicles: Retrospective analysis of candidemia epidemiology, species distribution, and antifungal susceptibility patterns in Bahrain.

Saeed N, Almusawi S, Al-Beltagi M World J Virol. 2024; 13(4):98839.

PMID: 39722764 PMC: 11551684. DOI: 10.5501/wjv.v13.i4.98839.


References
1.
Pareja J, Garland R, Koziel H . Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest. 1998; 113(5):1215-24. DOI: 10.1378/chest.113.5.1215. View

2.
Seaton R, Verma N, Naraqi S, Wembri J, Warrell D . The effect of corticosteroids on visual loss in Cryptococcus neoformans var. gattii meningitis. Trans R Soc Trop Med Hyg. 1997; 91(1):50-2. DOI: 10.1016/s0035-9203(97)90393-x. View

3.
Vergidis P, Avery R, Wheat L, Dotson J, Assi M, Antoun S . Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases. Clin Infect Dis. 2015; 61(3):409-17. PMC: 4796723. DOI: 10.1093/cid/civ299. View

4.
Nguyen N, Seitz B, Martus P, Langenbucher A, Cursiefen C . Long-term topical steroid treatment improves graft survival following normal-risk penetrating keratoplasty. Am J Ophthalmol. 2007; 144(2):318-9. DOI: 10.1016/j.ajo.2007.03.028. View

5.
Hansen K, St Clair E . Disseminated histoplasmosis in systemic lupus erythematosus: case report and review of the literature. Semin Arthritis Rheum. 1999; 28(3):193-9. DOI: 10.1016/s0049-0172(98)80036-x. View